Movement Alert｜Hims & Hers Health Inc. Rises 5.04% in Regular Trading, FDA Advisory Committee Backs Bpc-157 Peptide for Pharmacy Compounding

Market Focus07-24

On July 24, Hims & Hers Health Inc. rose 5.04% in regular trading, trading at $32.75/share, with turnover of $72.62 million. The rally was driven by the FDA advisory committee voting to include Bpc-157 peptide on the list of substances allowed for pharmacy compounding.

The company had actively advocated at panel meetings for the FDA to expand access to specific peptide medications. The regulatory body ultimately delivered a positive signal, validating the company's lobbying efforts. Market participants view this development as opening new business growth avenues for the telehealth platform, potentially broadening its prescription drug category coverage and creating incremental opportunities for its weight management and related services.

Additionally, Truist raised its price target on the stock to $27 from $23 while maintaining a Hold rating. The consensus mean price target stands at $30.69. Earlier this month, BofA Securities had also lifted its target to $36 from $25. The company recently completed its acquisition of Eucalyptus, expanding into Australia, Canada, and Germany.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111030039?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111030039","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Inc. Rises 5.04% in Regular Trading, FDA Advisory Committee Backs Bpc-157 Peptide for Pharmacy Compounding","media":"Market Focus","content":"<p><p>On July 24, Hims & Hers Health Inc. rose 5.04% in regular trading, trading at $32.75/share, with turnover of $72.62 million. The rally was driven by the FDA advisory committee voting to include Bpc-157 peptide on the list of substances allowed for pharmacy compounding.</p><p>The company had actively advocated at panel meetings for the FDA to expand access to specific peptide medications. The regulatory body ultimately delivered a positive signal, validating the company's lobbying efforts. Market participants view this development as opening new business growth avenues for the telehealth platform, potentially broadening its prescription drug category coverage and creating incremental opportunities for its weight management and related services.</p><p>Additionally, Truist raised its price target on the stock to $27 from $23 while maintaining a Hold rating. The consensus mean price target stands at $30.69. Earlier this month, BofA Securities had also lifted its target to $36 from $25. The company recently completed its acquisition of Eucalyptus, expanding into Australia, Canada, and Germany.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Inc. Rises 5.04% in Regular Trading, FDA Advisory Committee Backs Bpc-157 Peptide for Pharmacy Compounding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Inc. Rises 5.04% in Regular Trading, FDA Advisory Committee Backs Bpc-157 Peptide for Pharmacy Compounding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, Hims & Hers Health Inc. rose 5.04% in regular trading, trading at $32.75/share, with turnover of $72.62 million. The rally was driven by the FDA advisory committee voting to include Bpc-157 peptide on the list of substances allowed for pharmacy compounding.</p><p>The company had actively advocated at panel meetings for the FDA to expand access to specific peptide medications. The regulatory body ultimately delivered a positive signal, validating the company's lobbying efforts. Market participants view this development as opening new business growth avenues for the telehealth platform, potentially broadening its prescription drug category coverage and creating incremental opportunities for its weight management and related services.</p><p>Additionally, Truist raised its price target on the stock to $27 from $23 while maintaining a Hold rating. The consensus mean price target stands at $30.69. Earlier this month, BofA Securities had also lifted its target to $36 from $25. The company recently completed its acquisition of Eucalyptus, expanding into Australia, Canada, and Germany.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1111030039","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111030039","pubTimestamp":1784900340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, Hims & Hers Health Inc. rose 5.04% in regular trading, trading at $32.75/share, with turnover of $72.62 million. The rally was driven by the FDA advisory committee voting to include...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"动态警报|Hims & Hers Health Inc. 常规交易上涨 5.04%，FDA 咨询委员会支持 Bpc-157 肽用于药房复合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On July 24, Hims & Hers Health Inc. rose 5.04% in regular trading, trading at $32.75/share, with turnover of $72.62 million. The rally was driven by the FDA advisory committee voting to include Bpc-157 peptide on the list of substances allowed for pharmacy compounding.The company had actively advocated at panel meetings for the FDA to expand access to specific peptide medications. The regulatory body ultimately delivered a positive signal, validating the company's lobbying efforts. Market participants view this development as opening new business growth avenues for the telehealth platform, potentially broadening its prescription drug category coverage and creating incremental opportunities for its weight management and related services.Additionally, Truist raised its price target on the stock to $27 from $23 while maintaining a Hold rating. The consensus mean price target stands at $30.69. Earlier this month, BofA Securities had also lifted its target to $36 from $25. The company recently completed its acquisition of Eucalyptus, expanding into Australia, Canada, and Germany.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111030039","isCrawlerRequest":true}